{"title":"The invisible enemy?: Making the case for spreading depolarization monitoring.","authors":"Kazutaka Sugimoto","doi":"10.1080/14737175.2026.2762941","DOIUrl":"https://doi.org/10.1080/14737175.2026.2762941","url":null,"abstract":"","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1-3"},"PeriodicalIF":4.3,"publicationDate":"2026-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149417358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Weighing the evidence for glucagon-like peptide-1 (GLP-1) receptor agonists as a potential migraine therapy.","authors":"Geert A Sulter","doi":"10.1080/14737175.2026.2762940","DOIUrl":"https://doi.org/10.1080/14737175.2026.2762940","url":null,"abstract":"","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1-4"},"PeriodicalIF":4.3,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149403644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Lipid-lowering therapy for secondary stroke prevention beyond statin monotherapy: a mechanism-informed approach across drug classes and stroke subtypes.","authors":"Cheng-Yang Hsieh, Sheng-Feng Sung","doi":"10.1080/14737175.2026.2762938","DOIUrl":"https://doi.org/10.1080/14737175.2026.2762938","url":null,"abstract":"<p><strong>Introduction: </strong>Intensive lipid lowering is crucial for secondary prevention of ischemic stroke, but achieving low-density lipoprotein cholesterol (LDL-C) targets and selecting additional agents beyond statins are challenging. Stroke mechanisms vary in their contribution to atherosclerosis, so the benefits, risks, and treatment burdens of aggressive LDL-C reduction may differ among phenotypes.</p><p><strong>Areas covered: </strong>The authors searched PubMed/MEDLINE and Google Scholar for studies published through September 2026 on lipid-lowering therapy after ischemic stroke or transient ischemic attack. The authors prioritize randomized trials, subgroup analyses, stroke-specific observational studies, meta-analyses, and major guidelines or consensus documents and assess the evidence by study design, stroke phenotype, and whether outcomes were clinical events or surrogate measures, including LDL-C target attainment and plaque imaging.</p><p><strong>Expert opinion: </strong>Future lipid management after ischemic stroke could improve by combining stroke phenotype and atherosclerotic burden with established cardiovascular risk and LDL-C targets. Early combination therapy may help plaque-driven stroke patients reach targets, but its effect on recurrence is unproven. Evidence is limited by few stroke-specific trials, reliance on surrogate endpoints, and barriers including advanced imaging and biologic reimbursement. Phenotype-stratified trials should test whether mechanism-informed care improves outcomes and cost-effectiveness beyond guidelines.</p>","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1-18"},"PeriodicalIF":4.3,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149403643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Non-response in chronic migraine: separating residual afferent drive from drive-independent persistence.","authors":"Geert A Sulter","doi":"10.1080/14737175.2026.2762930","DOIUrl":"https://doi.org/10.1080/14737175.2026.2762930","url":null,"abstract":"<p><strong>Introduction: </strong>Around a third of patients with chronic migraine do not benefit from any available preventive drug, and the same predictors recur whether the failed agent was a calcitonin gene-related peptide (CGRP) ligand antibody, a receptor antagonist, onabotulinumtoxinA or candesartan.</p><p><strong>Areas covered: </strong>PubMed and ClinicalTrials.gov were searched from 2015 to 2026 for non-response, resistant and refractory migraine and for PACAP, amylin and potassium-channel targets, with reference lists hand-searched. Two explanations come first, neither biological: a percentage-reduction endpoint behaves differently at ceiling headache frequency, and acute medication overuse can produce failure of every class. What survives is compatible with two mechanisms rarely distinguished: afferent drive continuing through a channel the drug does not block, which PACAP and amylin make concrete, or persistence of the central pain state after drive has fallen. Allodynia measured between attacks rather than during them separates responders from non-responders, a first handle on the second mechanism.</p><p><strong>Expert opinion: </strong>Emerging targets are assigned to one mechanism or the other, with the result that would overturn each. Trials of PACAP-directed and amylin-directed agents recruited patients with prior failure of any class rather than of the CGRP pathway, leaving the claim most often made for these drugs untested.</p>","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1-15"},"PeriodicalIF":4.3,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149393315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Lacosamide in neuropathic pain and individualized patient care a response to the letter to the editor: lacosamide in neuropathic pain: a question of overall efficacy or patient selection?","authors":"Junad Khan","doi":"10.1080/14737175.2026.2761318","DOIUrl":"https://doi.org/10.1080/14737175.2026.2761318","url":null,"abstract":"","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1-2"},"PeriodicalIF":4.3,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149378176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Lacosamide in neuropathic pain: a question of overall efficacy or patient selection?","authors":"Antonio Alcántara Montero","doi":"10.1080/14737175.2026.2761320","DOIUrl":"https://doi.org/10.1080/14737175.2026.2761320","url":null,"abstract":"","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1-2"},"PeriodicalIF":4.3,"publicationDate":"2026-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149378177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Long-term outcomes and potential safety considerations of stem cell-based therapies for spinal cord injury.","authors":"Yuichiro Ichihara, Narihito Nagoshi","doi":"10.1080/14737175.2026.2753640","DOIUrl":"https://doi.org/10.1080/14737175.2026.2753640","url":null,"abstract":"<p><strong>Introduction: </strong>Stem cell-based therapies may promote recovery after spinal cord injury through cell replacement, reconstruction of disrupted neural circuits, and remyelination. Their clinical value depends not only on early neurological improvement but also on the durability of functional benefits and absence of delayed complications.</p><p><strong>Areas covered: </strong>This review examines long-term efficacy and safety evidence from preclinical and clinical studies of neural stem/progenitor cell products, pluripotent stem cell-derived neural and oligodendroglial products, and mesenchymal stromal cell products for spinal cord injury. The authors address graft survival and maturation, durability of neurological recovery, tumorigenicity, graft overgrowth, aberrant differentiation, immunological complications, maladaptive connectivity, manufacturing control, and post-transplant surveillance. English-language publications were identified through a PubMed/MEDLINE search from database inception through 4 October 2026, supplemented by reference-list screening. ClinicalTrials.gov was additionally consulted through 4 October 2026, to identify corresponding clinical programs and extended follow-up reports.</p><p><strong>Expert opinion: </strong>Clinical studies support feasibility and encouraging product-specific safety observations, but durable efficacy remains unproven. Current evidence derives from small, heterogeneous, and often uncontrolled cohorts with uneven long-term follow-up. Progress will require standardized manufacturing and potency criteria, sensitive monitoring of abnormal graft behavior, controlled efficacy studies, and coordinated long-term registries to detect rare or delayed adverse events.</p>","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1-17"},"PeriodicalIF":4.3,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149341429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The challenge of drug-related seizures: is identifying the cause only part of the battle?","authors":"Marco Mula","doi":"10.1080/14737175.2026.2752962","DOIUrl":"https://doi.org/10.1080/14737175.2026.2752962","url":null,"abstract":"","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1-4"},"PeriodicalIF":4.3,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149319514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"When sex matters early: clues from pediatric onset multiple sclerosis.","authors":"Lorena Lorefice, Robert Zivadinov","doi":"10.1080/14737175.2026.2744752","DOIUrl":"10.1080/14737175.2026.2744752","url":null,"abstract":"<p><strong>Introduction: </strong>Pediatric-onset multiple sclerosis (POMS) provides a unique developmental model to investigate when sex differences first emerge in multiple sclerosis (MS). As disease onset occurs during immune, endocrine, and neural maturation, POMS offers an opportunity to understand how puberty may shape disease susceptibility and subsequent trajectories.</p><p><strong>Areas covered: </strong>This review synthesizes evidence from epidemiological, clinical, neuroimaging, biomarker, and therapeutic studies across prepubertal, peripubertal, and post-pubertal stages. Articles published between 2000 and 2025 were identified through a PubMed/MEDLINE search using terms related to POMS, sex differences, and puberty. Available data indicate that the transition from childhood to adolescence coincides with the emergence of female predominance and sex-dependent patterns of tissue injury. MRI, retinal imaging, and fluid biomarkers suggest that differences in neuroaxonal vulnerability may be detectable early in the disease course. However, most studies remain sex-agnostic.</p><p><strong>Expert opinion: </strong>Sexual dimorphism in MS may emerge earlier than previously recognized, with puberty representing a critical window in which sex-related biological changes begin to shape disease susceptibility and expression. Incorporating sex and pubertal stage into longitudinal POMS research may help elucidate the mechanisms driving these differences, refine early risk stratification, and ultimately support more individualized therapeutic strategies across the MS lifespan.</p>","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1103-1114"},"PeriodicalIF":4.3,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149165631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Andrea Santangelo, Maria Cristina Maggio, Alessandro Orsini, Giuseppe Santangelo, Pasquale Striano, Giovanni Corsello
{"title":"Contemporary approaches to Sydenham's chorea - where evidence meets reality.","authors":"Andrea Santangelo, Maria Cristina Maggio, Alessandro Orsini, Giuseppe Santangelo, Pasquale Striano, Giovanni Corsello","doi":"10.1080/14737175.2026.2742388","DOIUrl":"10.1080/14737175.2026.2742388","url":null,"abstract":"<p><strong>Introduction: </strong>Sydenham's chorea (SC) is the most common acquired chorea of childhood and a major neurological manifestation of acute rheumatic fever. Although often considered self-limiting, it can cause substantial motor, psychiatric, cognitive, educational, and social morbidity, with relapses in a relevant proportion of patients.</p><p><strong>Areas covered: </strong>In this critical perspective, the authors critically examined current approaches to SC management, focusing on three complementary pillars: eradication of Group A β-hemolytic streptococcal infection and long-term secondary antibiotic prophylaxis; symptomatic control; and immunomodulation. Antibiotic prophylaxis is essential to prevent recurrent rheumatic fever, rheumatic heart disease progression, and neurological relapse, but does not treat the established autoimmune episode. Anti-seizure medicaments are generally preferred for symptomatic treatment because of their favorable efficacy-tolerability balance, while dopamine receptor antagonists should be reserved for severe hyperkinesia because of drug-induced movement disorders. Recent evidence supports earlier use of corticosteroids in moderate-to-severe or disabling SC, whereas intravenous immunoglobulin and plasma exchange remain escalation options for selected severe or steroid-resistant cases.</p><p><strong>Expert opinion: </strong>Treatment response should be assessed by functional recovery, not motor improvement alone. Future progress will depend on prospective registries, standardized outcome measures, pragmatic multicenter trials, and biomarker studies to enable more individualized therapeutic decisions. Systematic neuropsychiatric assessment and multidisciplinary support are therefore integral to comprehensive care.</p>","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1065-1074"},"PeriodicalIF":4.3,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149105975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}